Mood and Cognitive Effects of Psilocybin in Healthy Participants (MELO)
Double-blind, randomised, placebo-controlled, within-subject study (n=20) testing six low/microdoses of oral psilocybin (0, 1, 2, 5, 8, 10 mg) in healthy volunteers to identify doses that improve mood, cognition and sleep without hallucinogenic effects.
Details
This double-blind, randomised, placebo-controlled study administers six separate oral doses of MELOCIN (Psilocybe cubensis powder; 0, 1, 2, 5, 8, 10 mg psilocybin) across six weekly sessions in healthy volunteers to assess safety and potential low-dose effects on mood, cognition and sleep.
Each session involves ingestion of 10 capsules (composition varied to achieve the target dose; placebo day includes 9 placebo + 1 Chaga capsule to mimic after-taste). Sessions are 6–9 days apart with continuous monitoring and blood sampling at multiple acute time points and standardised psychological testing.
Primary objective is safety and tolerability of low/microdoses; secondary outcomes include magnitude of mood, physiological and cognitive effects across doses compared with placebo.